Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1995-06-06
1998-12-08
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
4241941, 4241931, 4241981, 4241781, 530399, 5303917, 5303919, A61K 3818
Patent
active
058465456
ABSTRACT:
Gytotoxic agents containing a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.
REFERENCES:
patent: 4169888 (1979-10-01), Hanka et al.
patent: 4301248 (1981-11-01), Nettleton et al.
patent: 4912227 (1990-03-01), Kelley et al.
patent: 5045451 (1991-09-01), Uhr et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5106951 (1992-04-01), Morgan et al.
patent: 5135736 (1992-08-01), Anderson et al.
Boyer et al., Antibody, Innumoconjugates and Radiopharmaceuticals, vol. 1, No. 2, pp. 105-162, 1988.
Waldmann, Science, vol. 252, pp. 1657-1662 (1991).
Roitt et al., Immunology, 3rd Edition, Mosby, St. Louis, pp. 17-19 (1993).
Osband et al., Immunology Today, vol. 11, No. 6, 1990, pp. 193-195.
U.S.A.N. 07/513,501, Paul A. Aristoff et al, Novel CC-1065 Analogs, Oct. 31, 1991, pp. 1-119, (publically available from WIPO).
Hermentin et al., Behring Inst. Mitt., No. 82, pp. 197-215 (1988).
Pierce Catalog, pp. E10-E45 (1992).
Carroll and Greene, Antibodies in Radiodiagnosis and Therapy, Zalutsky (Ed.) CRC Press, Boca Raton, Florida, pp. 13-43 (1989).
Coulter Catalog, pp. 27,34-35 and 40-41 (1992).
Pierce Catalog, pp. E10-E15, E20 and E44 (1991).
Kirkwood et al., Journal of Clinical Onocology, vol. 5, No. 8, pp. 1247-1255 (1987).
Murray et al., J. Nucl. Med., vol. 28, pp. 25-33 (1987).
Coulter Catalog, pp. 5-6, (1992).
Borrebaeck, Journal of Immunological Methods, vol. 123, pp. 157-165 (1989).
Boger et al., Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 2, pp. 115-120 (1991).
Reynolds et al., "The Chemistry Mechanism of Action and Biological Properties of CC-1065 A Potent Antitumor Antibiotic", Mar. 1986, pp. 319-334 (The Jour. of Antibiotics, vol. XXXIX, No. 3).
Martin et al., "CC-1065 Transformations", Jun. 1985, pp. 745-752, The Journal of Antibiotics, vol. XXXVIII, No. 6.
Warpehoski et al., "Stereoelectronic Factors Influencing the Biological Acitivity and DNA Interaction of Synthetic Antitumor Agents Modeled on CC-1065", 1988, pp. 590-603, J. Med. Chem., 31.
Ravi et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs", Jan. 1, 1992, pp. 127-131, Cancer Research, 52.
Boger et al., A Potent, Simple Derivative of an Analog of the CC1065 Alkylation Subunit, 1991, pp. 55-58, Bioorganic & Medicinal Chemistry Letters, vol. 1, No. 1.
McGovren et al., "Preliminary Toxicity Studies with the DNA-Binding Antibiotic, CC-1065", Jan. 1984, pp. 63-70, The Journal of Antibiotics, vol. XXXVII, No. 1.
Hanaka et al., "CC-1065 (NSC-298223), A new Antitumor Antiobiotic Production, In Vitro Biological Activity, Microbiological Assays and Taxonomy of the Producing Microoranism", Dec. 1978, pp. 1211-1217, The Journal of Antibiotics, vol. XXXI, No. 12.
Gomi et al., "Anticellular and Antitumor Activity of Duocarmycons Novel Antitumor Antibiotics", JPN J. Cancer Res., vol. 83, No. 1, pp. 113-120, 1992.
Riganti et al., "The Unique Interaction with Immunity of FCE 24517, an Antitumor Drug with a Novel Mode of Action", Int. J. Immunopharm., (United Kingdom), vol. 14, No. 2, pp. 239-251, 1992.
Lee et al., "Determination of the Structural Features of (+)-CC-1065 that are Responsible for Bending and Winding of DNA", Chem. Res. Toxicol., (USA), vol. 4, No. 2, pp. 203-213, 1991.
Swenson et al., "Evaluation of DNA binding characteristics of some CC-1065 Analogs", Chem. Biol. Interact., vol. 67, No. 3-4, pp. 199-213, 1988.
Li et al., "Adozelesin, a Selected Lead Among Cyclopropylpyrroloindole Analogs of the DNA-Binding Antibiotic, CC-1065", Invest. New Drugs, vol. 9, No. 2, pp. 137-148, 1991.
Ennis et al., "The EGF Receptor System as a Target for Antitumor Therapy", Cancer Invest., vol. 9, No. 5, pp. 553-562, 1991.
Gutowski et al., "Epidermal Growth Factor Receptor-reactive Monoclonal Antibodies: Xenograft Antitumor Activity Alone and as Drug Immunoconjugates", Cancer Res., vol. 51, No. 20, pp. 5471-5475, 1991.
Pardridge et al., "Selective Transport of an Anti-transferrin Receptor Antibody Through the Blood-brain barrier in vivo", J. Pharmacol. Exp. Ther., vol. 259, No. 1, pp. 66-70, 1991.
Boger, D.L. et al.: J. Org. Chem., vol. 55, 1990, pp. 5823-5833.
Boger, D.L. et al.: Biorg. Med. Chem. Lett., vol. 1, 1991, pp. 115-120.
Organic Chemistry, 3rd ed., p. 727.
Hack's Chemical Dictionary, 4th ed., 9. 35.
Blattler Walter A.
Chari Ravi V. J.
Goldmakher Viktor S.
Achutamurthy Ponnathapura
Immunogen Inc.
Wessendorf J. D.
LandOfFree
Targeted delivery of cyclopropylbenzindole-containing cytotoxic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted delivery of cyclopropylbenzindole-containing cytotoxic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery of cyclopropylbenzindole-containing cytotoxic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-174630